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dP/dtmax was recorded during Left Ventricular (LV) catheterization prior to and during
Phenylephrine (PE) [5-50 micrograms/minute]. Infarct size was measured by tetrazolium
and planimetry.
Results: Mean LV Ejection Fraction (EF) in the short axis in Group 1 was 88 + 3% at
baseline and decreased to 78 + 4% at 4 months (p=0.03). In Group 2, EF decreased
from baseline of 87 + 4% to 51 + 3% at 1 month (p=0.001) and did not change thereafter.
Although EF in Group 3 decreased from 87 + 4 % to 63 + 3% at 1 month, EF progres-
sively increased to 69+6% at 4 months, which was similar to controls but different than
Group 2 (p=0.02). Septal wall thickening in Group 3 was 57.9 + 11.6% at 4 months, which
was nearly identical to the control septal thickening of 59.2 + 8.9 %, and was significantly
greater than Group 2 septal thickening which was only 27.8 + 7% (p=0.02). dP/dtmax in
Group 3 increased from 3568 + 701 to 10062 + 784 mmHg/s (p=0.001) with PE 50 micro-
grams/minute which was similar to maximum control, but only increased from 3955 + 803
to a maximum value of 7534 + 941 mmHg/s in Group 2. The infarct sizes averaged
2.98% + 2.8% for Group 3 versus 22.1% + 5.6 % for Group 2 at three months (p=0.02)
and 9.2 % + 2.0 for Group 3 versus 40.0 + 9.2 for Group 2 (p=0.001) at four months. The
HUCBC migrated from the periphery into the infarction and were aligned and in register
with the host cardiomyocytes at 3 and 4 months.
Conclusion: HUCBC can significantly limit ischemic damage and improve LV function in
the infarcted rat heart.
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Background: Cell transplantation is becoming a viable strategy to improve revasculariza-
tion and left ventricular function after myocardial infarction (MI) injury. This study evalu-
ated the effect of trans-epicardial bone marrow (BM) cell transplantation on infarct size,
blood vessel formation and myocardial function in a porcine model of non-reperfused MI.
Methods: Coil implants were positioned in the coronary circulation of 13 domestic swine
to produce MI. Twenty-eight days later, autologous BM was aspirated, labeled with bro-
mdeoxyuridine (BrdU), and cultured for 48 hours. Animals underwent a left thoracotomy
and 0.2 ml of BM (~ 1.5 million cells/ml) were injected at 8 sites (1 cm apart) within the
infarcted and border regions of 8 swine; 5 animals injected with saline served as controls.
Animals received systemic BrdU 24 hours prior to euthanasia at 28 days. Regional con-
tractility was assessed by trans-epicardial echography performed at the time of BM injec-
tions and at the end of the study period.
Results: The infarct size (mm2 ) was smaller in the BM transplanted group (81.83±10.65)
than in the control group (147.72±23.25, p= 0.015). BrdU positive cells of BM treated and
controls were 51.66% and 29.19%, respectively. Further, α-actin positive cells were sig-
nificantly greater in the BM injected animals (BM= 314.8±37.4 vs. saline= 167.1±11.9/
0.1mm2, p=0.02) as well as the number of factor VIII positive endothelial cells (BM=
363.3±28.2 vs. saline= 254.4±28.1 cells/0.1mm2, p=0.03). The number of blood vessels
>50µm was significantly increased in the BM group=317.9± 54.9 vs 149.12±
6.08(p<0.05). Wall motion score index was similar in the BM injected and saline groups
at baseline (1.63±0.16 vs. 1.25±0.25, p=0.21) and at 28 days (1.83±0.22 vs. 1.63±0.38,
respectively, p=0.62).
Conclusion: BM cell engraftment of infarcted tissue is feasible with cell viability main-
tained up to 28 days and is an effective strategy for infarct size reduction. Increased
angiogenesis by BM transplantation in a model of non-reperfused MI was not sufficient to
support an improvement in left ventricular function.
1078-94 Acute Myocardial Infarction Is a Stimulus for Stem Cell 
Mobilisation and Elevated Erythropoietin Serum Levels
Korff Krause, K. Jaquet, K. Kyriazis, B. Fehse, C. Lange, A. Zander, K. H. Kuck, St. Georg 
Hospital, Hamburg, Germany, University of Hamburg, Hamburg, Germany
Introduction: Bone marrow derived stem cells have the capacity to home infarcted heart
tissue, and promote cardiac repair as shown in experimental data in animal models. So
we addressed the question wether progenitor cells that have been shown to differentiate
into endothelial cells and cardiomyocytes in vitro and in vivo are mobilized in peripheral
blood (PB) in patients with coronary heart disease (CHD) and determined growth factor
serum levels.
Methods: PB was taken from 16 pts. with acute myocardial infarction (AMI), 8 pts. with
angina pectoris (AP) an 10 pts. without CHD who underwent cornary angiogram (control)
and analysed with FACS analysis (percent/1 million cells). Growth factor and Epo serum
levels were determined with ELISA technique (mU/ml). Samples were drawn at time point
(TP) 1 (day 1-3 after ischemic event) and time point (TP) 2 (day 4-8).
Results: The mean values of CD34+, CD117+ and CD133+ cells were all elevated in pts.
with either AMI or AP compared to the control group. Pts. with AMI had doubled cell
counts of CD117+ and CD34+ progenitor cells in PB compared to pts. with AP. Epo was
significantly elevated in pts. with AP and AMI: 
Conclusion: Pts. with AMI have increased CD34+, CD117+ and CD133+ precursor cell
mobilisation after ischemic events. Acute myocardial infarction is a stimulus for CD117+
and CD34+ progenitor cell mobilisation and Epo may play a role in its regulation.
1078-95 Intracellular Calcium Regulates Tumor Necrosis Factor-
Alpha-Induced Embryonic Stem Cell Migration
Emel Kaplan, Yu Chen, Jiang-Yong Min, Jamal S. Rana, Qinen Ke, James P. Morgan, 
Beth Israel Deaconess Medical Center, Boston, MA
Background: Previously we have shown that after systemic injection of murine embryonic
stem cells (ESCs), these cells home to the hearts of mice suffering from myocarditis. The
purpose of this study was to visualize the migratory pattern of ESCs during TNF-alpha
induced chemotaxis and to test the association between intracellular calcium concentra-
tion ([Ca2+]i) and ESC motility.
Methods: We used high speed optical sectioning microscopy to observe and record the
behavior of ESCs. A direct viewing chemotaxis chamber with two concentric wells (Dunn
chamber) allowed us to establish a linear concentration gradient of TNF-alpha. ESCs
were suspended in a physiological buffer and maintained at 37 °C. Cell movement was
monitored every two minutes over a three hour period, using concentrations of TNF-
alpha of 2.0-10.0 ng/l (n=45). Changes in [Ca2+]i were measured with the fluorescent
dye fura-2/AM.
Results: At these concentrations of TNF-alpha we found that ESCs migrated towards
TNF-alpha in a dose-related manner with mean rates of 1.3-3.6 µm/min. The total move-
ment of the ESCs also varied with different concentrations of TNF-alpha. Furthermore,
TNF-alpha induced the formation of proteopodia, which in turn play an important role in
migration and homing of stem cells.
During migration ESCs showed an increase in intracellular Ca2+. To further investigate
the role of Ca2+ in the migration of ESCs, we monitored cells in the presence and
absence of extracellular Ca2+ and found that presence of extracellular Ca2+ had a posi-
tive effect on migration (n=20).
Conclusion: These results demonstrate that ESCs are highly motile and respond to differ-
ent concentrations of TNF-alpha in a dose-related manner. Also, an increased [Ca2+]i
has a positive effect on such a migration of ESCs. These mechanisms may play a critical
role in heart-specific homing of ESCs, after systemic injection.
1078-96 The Role of Collateral Circulation in the Acute Phase of 
ST-Segment Elevation Myocardial Infarction Treated 
With Primary Coronary Intervention
Peter Elsman, Arnoud W. J. van t' Hof, Kor Miedema, Stoffer Reiffers, Felix Zijlstra, Isala 
Klinieken, location Weezenlanden, Zwolle, The Netherlands
Background: The role of collateral flow in the first hours of infarction remains unclear.
Our aim was to determine whether angiographic evidence of coronary collateral flow has
a beneficial effect on infarct size and left ventricular function in acute myocardial infarc-
tion (MI) treated with early primary coronary intervention (PCI).
Methods: Between 1994 and 2001 1074 patients with acute MI treated with early PCI,
TIMI 0 or 1 flow at first contrast injection and technical adequate angiograms for collateral
flow detection were analysed.
Results: Comparing collateral flow grade 0, 1 and 2/3, increased collateral flow is associ-
ated with lower incidence of Killip class > 2 at presentation (12.% versus 9.8% versus
4%, p for trend 0.01), decreased use of intra aortic balloon pumping (IABP) post-PCI
(17.2% versus 12.8% versus 4.7%, p for trend 0.0005), better myocardial blush grade
(MBG)(MBG3: 21.2% versus 25.4% versus 29.2%, p for trend 0.04) and smaller enzy-
matic infarct size (LDHQ36) (1947±1553 U/l and 1893±1549 U/l versus 1221±767 U/l,
p=0.001). These beneficial effects are particular present in LAD related infarcts.
Conclusion: Presence of angiographically detectable collaterals have a protective effect
on enzymatic infarct size and pre- and post-intervention hemodynamic conditions in
patients with acute MI treated with early PCI, in particular when Rentrop grade 2/3 is
present and in LAD related infarcts.
1078-97 The Protective Effect of Edaravone on Myocardial 
Damage During Ischemia-Reperfusion in Rabbit Heart
Yujirou Tanabe, Shinji Okubo, Yachiyo Hoshiba, Kenji Takeda, Sumiyo Kudoh, Michihiko 
Kitayama, Seiyu Kanemitsu, Hiroichi Tsugawa, Noboru Takekoshi, Kanazawa Medical 
University, Uchinada, Japan
[Background]A free radical scavenger, edaravone has the ability to stimulate prostacy-
cline release and to inhibit the lipoxygenase pathway in the arachidonic acid cascade.
We demonstrated whether edaravone attenuates the myocardial damage in the
ischemia-reperfusion rabbit heart.
[Methods]All rabbits underwent sustained coronary artery occlusion(CAO) for 30 min fol-
lowed by 180 min of reperfusion. 1)Control(n=8), 2)Edaravone-early(n=8, 3mg/kg i.v):10
min before reperfusion, 3) Edaravone-immediately(n=8, 3mg/kg i.v):immediately after
reperfusion, and Edaravone-late(n=8, 3mg/kg i.v):5 min after reperfusion were studied.
Infarct size was determined by TTC staining. The percentage of apoptosis cells (nuclear
DNA fragmentation detection via fluorescence microscopy) was calculated and DNA lad-
der assay was prepared from the ischemic region.
[Results] 1)Infarct size as a percent of the area at risk in control was 42.8±5.2%. Edara-
vone-early (23.5±3.3%) and Edaravone-immediately (24.5±5.3%) were significantly
reduced infarct size (p<0.01) compared with control group. However, when edaravone
was present 5 min after reperfusion, protection was completely abolished (39.6±4.5%).
2) The findings of DNA fragmentation were significantly(p<0.01) decreased in Edara-
vone-early (2.5±1.8%) and Edaravone-immediately (3.2±1.8%) group compared with
control (15±3.9%) and Edaravone-late (13.5±3.3% ).DNA laddering were attenuated in
Edaravone-early and Edaravone-immediately group. [Conclusions] Single bolus adminis-
Time point 1 (mean) Time point 2 (mean)
CD34: AMI/AP/control (%) 0.21/0.19/0.10 0.31/0.27/0.12
CD117: AMI/AP/control (%) 0.09/0.05/0.06 0.30/0.05/0.06
CD133: AMI/AP/control (%) 0.20/0.21/0.11 0.19/0.11/0.10
Epo: AMI/AP/control, (mU/ml) 34.0/24.0/9.0 30.0/27.5/8.2
